Targretin gel (bexarotene topical) / Eisai, Bausch Health - LARVOL DELTA

Effective Use of Mogamulizumab in CD30+ Large Cell Transformed Mycosis Fungoides: A Case of Early Remission (EADV 2025) - "Materials & Methods/Case presentation: We report a case of a 66-year-old male with a 10-year history of MF (stage T2bN0M0B0 at diagnosis), managed with multiple lines of therapy including PUVA, UVB, bexarotene, topical nitrogen mustard (Mustargen), chlormethine gel (Ledaga), and methotrexate—all with partial or no sustained response. Although Brentuximab vedotin remains a first-line option for CD30+ LCT-MF, this case illustrates the potential of mogamulizumab to induce both hematologic and unexpectedly rapid cutaneous responses, even in transformed disease. To our knowledge, this is the first report demonstrating successful use of mogamulizumab in a patient with CD30+ LCT-MF with rapid response both in blood and skin. Mogamulizumab may represent a safe and effective alternative in select refractory cases."

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology • CCR4 • TNFRSF8

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (clinicaltrials.gov) - P=N/A | N=0 | Withdrawn | Sponsor: Case Comprehensive Cancer Center | N=22 ➔ 0 | Trial completion date: Mar 2026 ➔ Jun 2026 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Dec 2025 ➔ Jun 2025

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Cutaneous T-cell Lymphoma • Dermatology • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Comparison of the efficacy of treatment with clobetasol propionate or bexarotene in early-stage mycosis fungoides. (PubMed, An Bras Dermatol) - "Both topical bexarotene and topical clobetasol propionate were found to be effective in MF. Irritation symptoms were more common with topical bexarotene. Moreover, the remission period with topical bexarotene was significantly longer."

Clinical • Journal • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (clinicaltrials.gov) - P=N/A | N=22 | Not yet recruiting | Sponsor: Case Comprehensive Cancer Center | Trial completion date: Sep 2025 ➔ Mar 2026 | Trial primary completion date: Jul 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Cutaneous T-cell Lymphoma • Dermatology • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Combination of Chemotherapy with Topical Bexarotene in the Management of Advanced-Stage Mycosis Fungoides: A Case Report (EADV 2024) - "He described that he was followed for 23 years with the diagnosis of MF, and he used PUVA (70 sessions) , methotrexate (6 cycles) , NB-UVB (3 years) , interferon (1 year) , oral bexarotene (1 month) , extracorporeal photopheresis (6 months) , gemcitabine, cisplatin chemotherapy (3 cycles) , TSEBT (8 sessions) and was unresponsive to those treatments...The patient, who was evaluated together with hematology, was treated with bendamustine chemotherapy, and tumoral and plaque lesions were detected to regress. Upon an increase in lesions during follow-up treatment was switched to romidepsin and topical bexarotene was started to be applied to the tumoral and plaque lesions of the patient, in a one-day use-two-day break treatment scheme... Bexarotene is a retinoid that selectively binds retinoid X receptors (RXR) alpha, beta, and gamma, which regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene has been shown to inhibit the in..."

Case report • Clinical • Metastases • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Dermatology • Hematological Disorders • Infectious Disease • Mycosis Fungoides • Novel Coronavirus Disease • Oncology • CD4

Clinicopathological Features and Mortality in Patients With Folliculotropic Mycosis Fungoides: A Retrospective Analysis (SOHO 2024) - "The most commonly used medications were topical corticosteroids (95%), followed by oral bexarotene (40%), brentuximab (27%), retinoids (25%), topical nitrogen mustard (16%), topical bexarotene (16%), and histone deacetylase inhibitors (13%)... Stage, advanced age, infections, and baseline Hb/LDH impact the survival of FMF patients. Multiple different treatment approaches may be needed to achieve a good clinical response and prevent disease progression."

Retrospective data • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma • CD7

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (clinicaltrials.gov) - P=N/A | N=22 | Not yet recruiting | Sponsor: Case Comprehensive Cancer Center | Trial completion date: Feb 2025 ➔ Sep 2025 | Trial primary completion date: Dec 2024 ➔ Jul 2025

Trial completion date • Trial primary completion date • Cutaneous T-cell Lymphoma • Dermatology • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Topical Bexarotene: What is New? (INDERCOS 2024) - No abstract available

Dermatology

Chronic Radiation Dermatitis Secondary to Narrow-Band Ultraviolet B Therapy in a Patient With Primary Cutaneous CD8+ T-Cell Lymphoma With Cytotoxic Granules. (PubMed, Am J Dermatopathol) - "Conventional therapies for CD8+ cutaneous T-cell lymphoma include topical steroids, topical nitrogen mustard, topical bexarotene, ultraviolet B therapy, psoralen and ultraviolet A therapy, local radiotherapy, and interferon alfa; however, these treatments are often found to be ineffective. Presented is a case of CD8+ cutaneous T-cell lymphoma with near-complete response to narrow-band ultraviolet therapy because of chronic radiation dermatitis initially believed to be possible progression of a CD8+ cutaneous epidermotropic cytotoxic T-cell lymphoma."

Journal • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (clinicaltrials.gov) - P=N/A | N=22 | Not yet recruiting | Sponsor: Case Comprehensive Cancer Center | Trial completion date: Sep 2024 ➔ Feb 2025 | Trial primary completion date: Jun 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Cutaneous T-cell Lymphoma • Dermatology • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Toxic epidermal necrolysis possibly associated with mogamulizumab in a patient with Sézary syndrome (EORTC-CLTF 2023) - "Materials and In this case report, a 49-year-old man with Sézary syndrome (SS) received various treatments, including bexarotene and topical steroids for 4 months. This is the first case that suggests a possible association between mogamulizumab and TEN development in patients with SS, which warrants increased clinical vigilance and early histopathological correlation in patients who develop new skin lesions after initiating mogamulizumab treatment."

Clinical • Adult T-Cell Leukemia-Lymphoma • Cutaneous T-cell Lymphoma • Hematological Malignancies • Leukemia • Oncology • Sezary Syndrome • TRB

A new case of lymphomatoid papulosis and mycosis fungoides coexistence (WCD 2023) - "LyP treatment options include topical steroids, topical bexarotene, phototherapy, nitrogen mustard, methotrexate, and intralesional interferon. In our patient, the papules and ulcerated plaques regressed under treatment with methotrexate"

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Mycosis Fungoides • Oncology • Psoriasis • T Cell Non-Hodgkin Lymphoma • CD8 • IL2RA • ISG20 • TNFRSF8

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (clinicaltrials.gov) - P=N/A | N=22 | Not yet recruiting | Sponsor: Case Comprehensive Cancer Center | Trial primary completion date: Jul 2023 ➔ Jun 2024

Trial primary completion date • Cutaneous T-cell Lymphoma • Dermatology • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Cutaneous T-cell lymphoma—Focus on some problems, and some solutions (ICML 2023) - "The therapeutic possibilities are unfortunately limited and include: skin moisturization, topical corticosteroids, topical mechlorethamine (nitrogen mustard), topical carmustine (BCNU), topical targretin 1%, topical imiquimod 5%, phototherapy (PUVA, UBV 311 nm), retinoids (acitretin, isotretinoin, targretin), interferon-alpha, methotrexate, biological treatments (brentuximab vedotin, alemtuzumab, mogalizumab, rituximab), extracorporal photopheresis, radiotherapy, surgery, stem cell transplantation, histone deacetylase inhibitors, chemotherapy...I strongly advise all specialists treating patients with cutaneous lymphomas to constantly checking their particular suffering, in order to assist them whenever possible. I also recommend referring patients to patient helping groups (some examples: www.krebsliga.ch and www.clfoundation.org)."

IO biomarker • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • CD4 • CD5 • CD7 • CD8 • DPP4 • PD-1

Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides. (PubMed, Healthcare (Basel)) - "Skin directed therapy includes steroids, nitrogen mustard, bexarotene gel, phototherapy UVB, and photochemiotherapy, i.e., total skin electron radiotherapy. Systemic therapies include retinoids, bexarotene, interferon, histone deacetylase inhibitors, photopheresis, targeted immunotherapy, and cytotoxic chemotherapy. Complexity of mycosis fungoides associated with long-term chronic evolution and multiple therapy based on disease stage need a multidisciplinary team approach to be treated."

IO biomarker • Journal • Review • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma • CD4

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Nov 2022 ➔ Mar 2022

Trial completion • Trial completion date • Breast Cancer • Oncology • Solid Tumor • BRCA • BRCA1 • BRCA2

Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer. (PubMed, Cancer Prev Res (Phila)) - "Maculopapular rash at the treatment site was the most common adverse event related to study drug and resolved within a few days of discontinuation. Bexarotene was detectable in breast tissue at the 10mg daily every other day dose."

Journal • P1 data • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • BRCA • CCND1

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (clinicaltrials.gov) - P=N/A | N=22 | Not yet recruiting | Sponsor: Case Comprehensive Cancer Center | Initiation date: Aug 2022 ➔ Dec 2022

Trial initiation date • Cutaneous T-cell Lymphoma • Dermatology • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Complete remission with bexarotene gel in unilesional folliculotropic mycosis fungoides located on the scalp. (PubMed, Dermatol Ther) - No abstract available

Journal • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (clinicaltrials.gov) - P=N/A; N=22; Not yet recruiting; Sponsor: Case Comprehensive Cancer Center; Trial completion date: Sep 2022 ➔ Sep 2024; Initiation date: Jan 2022 ➔ Aug 2022; Trial primary completion date: Jul 2022 ➔ Jul 2023

Trial completion date • Trial initiation date • Trial primary completion date • Cutaneous T-cell Lymphoma • Dermatology • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (clinicaltrials.gov) - P=N/A; N=22; Not yet recruiting; Sponsor: Case Comprehensive Cancer Center

New trial • Cutaneous T-cell Lymphoma • Dermatology • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

A phase I dose escalation study of topical bexarotene in women at high risk for breast cancer (SABCS 2018) - "Background: Breast cancer prevention with anti-estrogens, including tamoxifen, raloxifene, and exemestane, has been shown to reduce the incidence of hormone receptor-positive breast cancer. Secondary endpoints include serum bexarotene level, tissue bexarotene levels, and changes in thyroid function tests, lipid profile, and calcium. The planned accrual for this study if maximally accrued to all dose levels and the dose expansion cohort will be 40 participants. "

BRCA Biomarker • Clinical • P1 data • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

[VIRTUAL] Interim analysis of a phase I dose escalation study of topical bexarotene in women at high risk for breast cancer (SABCS 2020) - "Background: Breast cancer prevention with anti-estrogens, including tamoxifen, raloxifene, and exemestane, has been shown to reduce the incidence of hormone receptor-positive breast cancer. Maculopapular rash at treatment site was the most common adverse event related to study drug and resolved with discontinuation. Analysis is ongoing to assess bexarotene drug levels in serum and breast tissue samples."

Clinical • P1 data • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • BRCA • CCND1 • ER

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer (clinicaltrials.gov) - P1; N=27; Active, not recruiting; Sponsor: National Cancer Institute (NCI); N=40 ➔ 27

Clinical • Enrollment change • Breast Cancer • Oncology • Solid Tumor • BRCA • BRCA1 • BRCA2 • MRI

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Recruiting ➔ Active, not recruiting; Trial primary completion date: Nov 2022 ➔ Aug 2021

Clinical • Enrollment closed • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • BRCA • BRCA1 • BRCA2 • MRI